-
Electronic (PDF)
-
Site License
-
Enterprisewide
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
GlobalData, December 2011, Pages: 85
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Idiopathic Pulmonary Fibrosis (IPF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global IPF market. The report identifies the key trends shaping and driving the global IPF market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global IPF sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData valued the global idiopathic pulmonary fibrosis (IPF) therapeutics market at $74.0m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 50.2% over the next eight years to reach $1919.9m in 2018. This high growth rate can be attributed to the expected launch of Esbriet (pirfenidone) in Europe in 2012 (except for Germany, where it is expected to be launched in September 2011). In Japan, pirfenidone is known as Pirespa and in Europe and the US it is known as Esbriet. Pirespa (pirfenidone) was approved in Japan in 2008 and it is the only approved drug to date for the treatment of IPF. Being the first drug to be approved for IPF, it was set at a premium price in Japan. In spite of its high price, it achieved a significant market share with sales of $35m within two years of its launch. This signifies that the product acceptance for Pirespa was high in Japan. Esbriet is expected to show a similar trend after its launch in Europe and the US. Another drug, Vargatef (BIBF 1120), is also expected to be launched during the forecast period, which will provide further impetus to the IPF market. Esbriet is expected to be launched in the US in 2014. In May 2010, the FDA rejected InterMune’s application for the approval of Esbriet in the US, requesting an additional clinical study. InterMune has commenced enrollment for a new Phase III study, ASCEND (Assessment of Pirfenidone to Confirm Efficacy and Safety in IPF), results for which are expected to be available in mid-2013. InterMune anticipates a New Drug Application (NDA) resubmission for pirfenidone in the second half of 2013 and FDA action in the first half of 2014.
Scope
The report provides information on the key drivers and challenges of the IPF market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) IPF market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as TGF ß1 inhibitor, triple growth factor kinase inhibitor, phosphodiesterase Type 5 inhibitor, monoclonal antibody against connective tissue growth factor, JNK inhibitor, endothelin receptor antagonist, monoclonal antibody targeting integrin avß6, monoclonal antibody against human lysyloxidase-like-2 protein, bovine type V collagen, recombinant human protein pentraxin-2, bi-specific interleukin4 /interleukin 13 antibody, lysophosphatidic acid 1 receptor antagonist, a compound consisting of interleukin 13 and cytotoxic agent P38, lipid targeting monoclonal antibody, pan-isoform inhibitor of phosphatidylinositol-3-kinase, immunoadulator, NOX1/NOX4 inhibitor, telomerase activator, pan-phosphodiesterase inhibitor, retinoic acid signaling modulator and others.
- Analysis of the current and future competition in the global IPF market. Key market players covered are Actelion Ltd., Boehringer Ingelheim, Celgene Corporation, Fibrogen Inc and InterMune Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the IPF therapeutics market.
- Analysis of key recent licensing and partnership agreements in IPF market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global IPF market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global IPF market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global IPF market landscape? – Identify, understand and capitalize.
Keywords
Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials
1
1
1.1 List of Tables
1.2 List of Figures
2 IPF Therapeutics - Introduction
2.1 Disease Overview
2.1.1 Interstitial Lung Disease -
2.1.2 Idiopathic Interstitial Pneumonia -
2.1.3 Idiopathic Pulmonary Fibrosis -
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Primary Clinical Assessment - History and Physical Examination
2.5.2 Laboratory Tests
2.5.3 Imaging Studies
2.5.4 Other Tests
2.5.5 Procedures
2.6 Treatment and Management Options
2.6.1 Pharmacologic Treatment
2.6.2 Non Pharmacologic Treatment
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance
3 IPF Therapeutics - Market Characterization
3.1 IPF Therapeutics Market Size (2005 - 2010) - Global
3.2 IPF Therapeutics Market Forecast (2010 - 2018) - Global
3.3 IPF Therapeutics Market Size (2005 - 2010) - The US
3.4 IPF Therapeutics Market Forecast (2010 - 2018) - The US
3.5 IPF Therapeutics Market Size (2005 - 2010) - France
3.6 IPF Therapeutics Market Forecast (2010 - 2018) - France
3.7 IPF Therapeutics Market Size (2005 - 2010) - Germany
3.8 IPF Therapeutics Market Forecast (2010 - 2018) - Germany
3.9 IPF Therapeutics Market Size (2005 - 2010) - Italy
3.10 IPF Therapeutics Market Forecast (2010 - 2018) - Italy
3.11 IPF Therapeutics Market Size (2005 - 2010) - Spain
3.12 IPF Therapeutics Market Forecast (2010 - 2018) - Spain
3.13 IPF Therapeutics Market Size (2005 - 2010) - The UK
3.14 IPF Therapeutics Market Forecast (2010 - 2018) - The UK
3.15 IPF Therapeutics Market Size (2005 - 2010) - Japan
3.16 IPF Therapeutics Market Forecast (2010 - 2018) - Japan
3.17 Drivers and Barriers for the IPF Therapeutics Market
3.17.1 Drivers for the IPF Therapeutics Market
3.17.2 Barriers for the IPF Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 IPF Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the IPF Therapeutics Market
4.3.1 Pirespa/Esbriet (pirfenidone)
4.3.2 Prednisone
4.3.3 Azathioprine
4.3.4 Cyclophosphamide
4.4 Key Takeaway
5 IPF Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 IPF Therapeutics Pipeline - Pipeline by Phases of Development
5.3.1 IPF Therapeutics - Phase III Pipeline
5.3.2 IPF Therapeutics - Phase II Pipeline
5.3.3 IPF Therapeutics - Phase I Pipeline
5.3.4 IPF Market - Pre-Clinical Pipeline
5.3.5 IPF Market - Discovery Pipeline
5.3.6 Technology Trends Analytic Framework
5.4 IPF Therapeutics Market - Clinical Pipeline by Mechanism of Action
5.5 IPF Therapeutics - Promising Drugs Under Clinical Development
5.6 Molecule Profile for Promising Drug Under Clinical Development
5.6.1 BIBF-1120
5.7 Key Takeaway
6 IPF Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in IPF Therapeutics Clinical Trials
7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 IPF Therapeutics - Implications for Future Market Competition
8 IPF Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Actelion Ltd.
8.2.2 Boehringer Ingelheim GmbH
8.2.3 Celgene Corporation
8.2.4 Fibrogen, Inc.
8.2.5 InterMune, Inc.
8.2.6 Other Companies in the IPF Therapeutics Market
9 IPF Therapeutics - Licensing and Partnership Deals
10 IPF Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
1.1 List of Tables
Table 1: IPF Therapeutics - Histological and Clinical Classification of IIP
Table 2: IPF Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Table 3: IPF Therapeutics Market, Global, Forecasts ($m), 2010 - 2018
Table 4: IPF Therapeutics Market, The US, Revenue ($m), 2005 - 2010
Table 5: IPF Therapeutics Market, The US, Forecasts ($m), 2010 - 2018
Table 6: IPF Therapeutics Market, France, Revenue ($m), 2005 - 2010
Table 7: IPF Therapeutics Market, France, Forecasts ($m), 2010 - 2018
Table 8: IPF Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Table 9: IPF Therapeutics Market, Germany, Forecasts ($m), 2010 - 2018
Table 10: IPF Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Table 11: IPF Therapeutics Market, Italy, Forecasts ($m), 2010 - 2018
Table 12: IPF Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Table 13: IPF Therapeutics Market, Spain, Forecasts ($m), 2010 - 2018
Table 14: IPF Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Table 15: IPF Therapeutics Market, The UK, Forecasts ($m), 2010 - 2018
Table 16: IPF Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Table 17: IPF Therapeutics Market, Japan, Forecasts ($m), 2010 - 2018
Table 18: IPF Therapeutics-Adverse Events Related to Pirespa
Table 19: IPF Therapeutics, Phase III Pipeline, 2011
Table 20: IPF Therapeutics, Phase II Pipeline, 2011
Table 21: IPF Therapeutics, Phase I Pipeline, 2011
Table 22: IPF Therapeutics, Pre-Clinical Pipeline, 2011
Table 23: IPF Therapeutics, Discovery Pipeline, 2011
Table 24: IPF Therapeutics, Most Promising Drugs Under Clinical Development, 2011
Table 25: IPF Therapeutics, Efficacy of BIBF-1120
Table 26: IPF Therapeutics, Clinical Trials by Country, 2011
Table 27: IPF Therapeutics - Clinical Trials by Phase, 2011
Table 28: IPF Therapeutics, Clinical Trials by Status (%), 2011
Table 29: IPF Therapeutics, Prominent Sponsors, 2011
Table 30: IPF Therapeutics, Top Companies Participating in Clinical Trials, 2011
Table 31: Actelion Ltd., Respiratory Pipeline, 2011
Table 32: Boehringer Ingelheim GmbH, Respiratory Pipeline, 2011
Table 33: Celgene Corporation, Respiratory Pipeline, 2011
Table 34: Fibrogen, Inc., Respiratory Pipeline, 2011
Table 35: InterMune, Inc., Respiratory Pipeline, 2011
Table 36: IPF Therapeutics Market, Future Players
Table 37: IPF Therapeutics, Global, Deals, 2009-2011
1.2 List of Figures
Figure 1: IPF Therapeutics - Classification of Interstitial Lung Disease
Figure 2: IPF Therapeutics - Pathophysiology
Figure 3: IPF Therapeutics - Pathophysiology
Figure 4: IPF Therapeutics - Pathophysiology
Figure 5: IPF Therapeutics - Pathophysiology
Figure 6: IPF Therapeutics - Pathophysiology
Figure 7: IPF Therapeutics - Finger Clubbing in IPF Patients
Figure 8: IPF Therapeutics - Diagnosis Of IPF
Figure 9: IPF Therapeutics - Chest Radiograph
Figure 10: IPF Therapeutics - HRCT image
Figure 11: IPF Therapeutics - Referral Pathway
Figure 12: IPF Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Figure 13: IPF Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Figure 14: IPF Therapeutics Market, The US, Revenue ($m), 2005 - 2010
Figure 15: IPF Therapeutics Market, The US, Forecast ($m), 2010 - 2018
Figure 16: IPF Therapeutics Market, France, Revenue ($m), 2005 - 2010
Figure 17: IPF Therapeutics Market, France, Forecast ($m), 2010 - 2018
Figure 18: IPF Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Figure 19: IPF Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Figure 20: IPF Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Figure 21: IPF Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Figure 22: IPF Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Figure 23: IPF Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Figure 24: IPF Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Figure 25: IPF Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Figure 26: IPF Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Figure 27: IPF Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Figure 28: Opportunity and Unmet Need in the IPF Therapeutics Market, 2010
Figure 29: IPF Therapeutics, Strategic Competitor Assessment, 2010
Figure 30: IPF Therapeutics - Pipeline by Phase of Development, 2011
Figure 31: IPF Therapeutics, Technology Trends Analytics Framework, 2011
Figure 32: IPF Therapeutics, Technology Trends Analytics Framework, Description, 2011
Figure 33: IPF Therapeutics, Pipeline by Mechanism of Action (%), 2011
Figure 34: IPF Therapeutics, Chemical Structure of BIBF-1120
Figure 35: IPF Therapeutics - Clinical Trials by Country, 2011
Figure 36: IPF Therapeutics, Clinical Trials by Phase (%), 2011
Figure 37: IPF Therapeutics, Clinical Trials by Status (%), 2011
Figure 38: IPF Therapeutics, Overall Sponsors (%), 2011
Figure 39: IPF Therapeutics, Prominent Sponsors (%), 2011
Figure 40: IPF Therapeutics, Top Companies Participating in Clinical Trials, 2011
Figure 41: IPF Therapeutics Market, Drivers and Restraints, 2011
Figure 42: Implications for Future Market Competition in the IPF Market, 2011
Figure 43: IPF Therapeutics Market, Pipeline by Company, 2011
Figure 44: GlobalData Market Forecasting Model
Actelion Ltd.
Boehringer Ingelheim GmbH
Celgene Corporation
Fibrogen, Inc.
InterMune, Inc.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
